Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of ONCOZ.ST is 12 and suggests 92% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell